Wednesday, 26 November 2014

Nutraceutical Ingredients Market Research - 2017

Nutraceuticals are essentially products that provide therapeutic, medicinal, or pharmacological benefits besides providing nutrition. A nutraceutical ingredient is the key functional constituent of nutraceuticals. Such ingredients could be of diverse forms, ranging from chemical compounds to naturally occurring substances to bioactive substances; but their purpose remains common—to promote health and well-being and to prevent diseases.

Browse the detailed TOC at Nutraceutical Ingredients Market http://www.transparencymarketresearch.com/nutraceutical-ingredients-market.html

A growing geriatric population together with rising incidences of chronic diseases has spurred numerous concerns pertaining to health among the populace. These concerns have fuelled the market for nutraceuticals and nutraceutical ingredients to a great degree. For instance, more and more consumers are now picking healthier food products off shelves. The focus is shifting from mere hunger satisfaction to meeting nutritional needs. Food products that prevent nutrient deficiency or fight factors leading to various diseases are now perceived as being healthier and hence are becoming a preferred choice of many customers.

What works in the favor of nutraceuticals is their relative nascence from the global standpoint. While nutraceuticals are considered as being widely popular in developed countries, the same cannot be said of other developing or emerging regions globally. The very concept of nutraceuticals is a modern one leaving a significant scope for its development and further exploration.


Manufacturers stand to capitalize from the fact that herbal ingredients used in nutraceutical products are perceived as being highly effective by consumers in many developing nations. This lends considerable hope for the future growth prospects of the nutraceuticals industry in general and the nutraceutical ingredients industry in particular. Nutraceutical ingredients lie at the heart of the nutraceutical industry, as the quality of ingredients determines the market for a particular product. Thus, it is evident that the nutraceutical ingredients industry possesses its own market space and opportunities for growth. Typically, it has been observed in the case of such interdependent industries that the impact of the ingredients or raw material industry is more significant on the product industry.

Browse the full Press Release of Nutraceutical Ingredient Market: http://www.transparencymarketresearch.com/pressrelease/nutraceutical-ingredients-market.htm


Nutraceutical ingredients are most extensively used in applications such as dietary supplements, personal care products, functional food and beverages, as well as the animal nutrition industry. These applications are the dominant ones for the nutraceutical ingredients industry.

This report presents an analysis of the global nutraceutical ingredients market in USD million by diving the overall market into segments such as: weight control, body building, pain relief, and controlling diabetes. This report lays forth a detailed landscape of the nutraceutical ingredients industry by analyzing geographic markets such as North America, Eastern Europe, Western Europe, Latin America, Asia Pacific, and MEA.


The report offers annual estimates as well as forecasts from 2012 through 2017, in addition to providing a five-year historic analysis for the geographical markets mentioned previously.

THE REPORT OFFERS A COMPREHENSIVE OVERVIEW OF:

  • Factors propelling and inhibiting market growth
  • Opportunities within the market—by geography and segments
  • The very latest trends analysis of the industry
  • Detailed insights into the market size as well as forecasts of the same
  • Review of innovative product development and key research/development projects underway worldwide

REASONS TO PURCHASE THIS REPORT

  • Leading industry opinion keeps you abreast of latest news and trends
  • Forward-looking outlook on a category, market or issue affecting the industry
  • Six-year forecast to assess predictions pertaining to market growth
  • A detailed understanding of the competitive landscape, the leading players and brands
  • Analysis and review of the changing competitive landscape
  • A facts- and figures-based overview of the projected market performance
  • A forecast of sales as well as the other key pipeline projects from 2012 through 2017 for leading geographical regions
KEY SEGMENTS ANALYZED

  • BODY BUILDING
  • Probiotics and Prebiotics
  • Proteins
  • Peptides
  • Amino acids
  • Soy-based ingredients
  • Omega 3

WEIGHT CONTROL

  • Fibers and carbohydrates
  • Minerals
  • Vitamins & premixes

CONTROLLING DIABETES

  • Antioxidants & Carotenoids
  • Dairy-based Ingredients

PAIN RELIEF

  • Nutritional lipids and oils
  • Phytochemicals & Plant extracts
GEOGRAPHY

  • North America
  • Western Europe
  • Asia Pacific
  • Latin America
  • Eastern Europe
  • MEA


About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Monday, 24 November 2014

Europe Ambulatory Surgical & Emergency Center Services Market Size 2014 - 2020


Ambulatory surgery is defined as the admission of patients for planned surgical procedures and discharge on the same day. Ambulatory surgical and emergency center service offers cost-effective and time saving approach to facilitate variety of ophthalmology, urology, gastrointestinal, orthopedic, vascular, pulmonary, pain management and other surgeries.

Browse Europe Ambulatory Surgical & Emergency Center Services Market Report with Full TOC at http://www.transparencymarketresearch.com/europe-ambulatory-surgical-emergency-center-services-market.html

Ambulatory surgical process is been increasingly accepted by the patient population in Europe as these surgeries provides safe, high quality and innovative approach for surgical interventions. Positive efforts by European government to promote ambulatory surgeries and technological advancements further boost the market growth of ambulatory surgery in near future. Advancement in operative techniques and surgical instruments would enable more complex surgeries such as retinal detachment, disc operation and pars plana vitrectomy to be performed under ambulatory basis hence drives the market growth. These all factors collectively propel the need of ambulatory surgical services during the forecast period thus, stimulates the market growth. The market overview section of the report includes detailed qualitative analysis of the factors responsible for driving and restraining the growth of the ambulatory surgery market and future opportunities for this market. PESTLE analysis has been done while estimating individual countries in order to provide current as well as future status.

Europe Ambulatory Surgical and Emergency Center Market report provides an in-depth and comprehensive analysis of the Europe Ambulatory Surgical and Emergency Center Services market on the basis of types of procedures and the major European countries. In types of procedure segment, the report covers different types of surgical procedures that can be performed on day basis. Types of procedure segment includes surgeries such as ophthalmology, gastrointestinal, pain management, orthopedic, dermatology, ear, nose and throat (ENT), urology, obstetrics, vascular, general surgery and pulmonary. The market size and forecast in terms of USD million and market volume for each type of procedures has been provided for the period 2012 to 2020, considering 2013 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2014 to 2020 for each segment.

Geographically, the Europe Ambulatory Surgical and Emergency Center Services market is categorized as U.K., Germany, France, Italy, Spain, Belgium and Rest of the Europe. The market size (in terms of value and volume) and forecast for each country has been provided for the period 2012 to 2020, considering 2013 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2014 to 2020 for each segment.


A list of recommendations for existing as well as new entrants has also been discussed in the study to help in decision making and to develop future growth strategies. The report concludes with company profiles of key players operating in various segments of the market. Each company profile includes business overview, financial overview, product portfolio, business strategies and recent developments of the respective company.


Some of the prominent players in the ambulatory surgery market that have been profiled in this report are IntegraMed America, Inc., AmSurg Corporation, Nueterra Healthcare, Terveystalo Healthcare Oyj, Symbion, Inc., Medical Facilities Corporation, Surgery Partners, Healthway Medical Corporation Ltd., Eifelhoehen-Klinik AG, Community Health Systems, Inc. and others. Market players are profiled in this report on the basis of attributes such as company overview, financial overview, business strategies adopted by the companies to ensure sustainability and maximize profits and product portfolio, and recent developments.

The Europe Ambulatory Surgical and Emergency Center Services market is segmented as follows:

Europe Ambulatory Surgical and Emergency Center Services Market, by Types of Procedures
Ophthalmology
Gastrointestinal
Pain Management
Orthopedics
Dermatology
ENT
Urology
Obstetrics
Vascular
General Surgery
Pulmonary

Europe Ambulatory Surgical and Emergency Center Services Market, by Country
U.K.
Germany
France
Italy
Spain
Belgium
Rest of the Europe (RoE)

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Antibacterial Drugs Market Overview 2013 - 2019

This report on antibacterial drugs market studies the current as well as future prospects of the market globally. Antibacterial drugs are agents that are utilized to check the growth of bacterial strains in living organisms, which are responsible for several mild to severe infections. These drugs exhibit bactericidal activity that targets different physiological processes of harmful bacteria, such as, nucleic acid synthesis, cell wall synthesis, protein synthesis, and permeability of cell membrane, thus help treat various infections. This report comprises an elaborate executive summary, which includes a market snapshot that provides overall information of various segments and sub-segments that are contained in the report. It also provides an overall information and data analysis of the global antibacterial drugs market with respect to market segments based on drug class, and geographic regions.

Browse Global Antibacterial Drugs Market Report with Full TOC at http://www.transparencymarketresearch.com/antibacterial-drugs-market.html

The market for antibacterial drugs is segmented based on major classes of drugs, namely, aminoglycosides, β-lactams, tetracyclines, sulfonamides, quinolones/fluoroquinolones, macrolides and phenicols. The market for these classes has been extensively analyzed based on the leading drug launch, expiry, efficacy, sales revenue and geographic presence. The market size and forecast in terms of USD million for each of these classes has been provided for the period 2011 to 2019. β-lactams being the largest drug class, has been further classified into three major sub-segments, namely, penicillins, carbapenems, and cephalosporins. Elaborate qualitative information for these subclasses has been provided in separate sub-sections of this report. The report on antibacterial drugs market also provides value percent of compounded annual growth rate (CAGR) for each market segment for the forecast period 2013 to 2019, considering 2012 as the base year.

Geographically, the antibacterial drugs market has been categorized into four regions namely, North America, Europe, Asia-Pacific, and Rest of the World (ROW). The market sizes and forecasts for each of these regions have been provided for the period 2011 to 2019 along with CAGR (Value %) for the forecast period 2013 to 2019. The research study also incorporates the competitive scenario in these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of global antibacterial drugs market and future opportunities has been provided in the market overview section. This section of the report also deals with market attractiveness analysis and Porter’s five forces analysis for the antibacterial drugs market.


The report also includes pipeline analysis for the antibacterial drugs market that comprises sales forecast for various drugs currently under phase III clinical trials and expected to be launched within the forecast period. Some of the major drugs that have been profiled in this section include Tedizolid, Dalbavancin, Oritavancin, Delafloxacin, Ceftolozane/Tazobactam, CAZ-AVI, Surotomycin, Solithromycin, Eravacycline, MK-3415A and Delamanid. The forecast market size in terms of USD million for each of these drugs has been provided for the period 2013 to 2019, considering their launch during the forecast period. This chapter also provides % compounded annual growth rate (CAGR) for each drug for the forecast period 2013 to 2019. This report also includes a chapter on competitive landscape that includes market share analysis of the leading players in the antibacterial drugs market, in terms of their market share (Value %) in the year 2012. A list of recommendations has also been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share.


The report also profiles major players of the antibacterial drugs market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Some of the major players profiled in this report include AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly & Co., Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi.


The global antibacterial drugs market is segmented as follows:

Antibacterial Drugs Market, by Class
Aminoglycosides
β-Lactams
Tetracyclines
Sulfonamides
Quinolones/Fluoroquinolones
Macrolides
Phenicols

Antibacterial Drugs Market, by Geography
North America
Europe
Asia-Pacific
Rest of the World (RoW)

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com


Mouth Ulcers Treatment Market Analysis 2014 - 2020

Mouth ulcers, also known as aphthous ulcers, are painful open sores or lesions that are mostly found inside the mouth, either singly or in clusters. Mouth ulcers are extremely common and the prevalence rate is 2% to 60% among the global population. Various classes of drugs such as corticosteroid, analgesic, anesthetic, antihistamine and antimicrobial are utilized for the treatment of mouth ulcers. This research report on mouth ulcers treatment market explains various advancements occurring in this market and analyzes the global mouth ulcers treatment market by formulation, indication, drug class as well as geographic regions. This report comprises an elaborate executive summary, which includes a market snapshot that provides market dynamics of various segments and sub-segments that are included in the report in a precise manner.

Browse Mouth Ulcers Treatment Market Report with Full TOC at http://www.transparencymarketresearch.com/mouth-ulcers-treatment.html

A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global mouth ulcers treatment market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis and Porter’s five forces analysis and key players’ heat map analysis in 2013 in the mouth ulcers treatment market. Mouth ulcers treatment market report also explains about positive and negative factors for each of the formulations, drug class as well as indications.

The global market for mouth ulcers is segmented based on formulation into mouthwash, gels, spray and lozenge. The market for these formulations has been extensively analyzed based on consistency, effectiveness and sales revenue of the various formulations developed by the manufacturers. The market size and forecast in terms of USD million for each formulation has been provided for the period 2012 to 2020. The report on the mouth ulcers treatment market also provides % compounded annual growth rate (CAGR) for each of the aforementioned market segment and sub segment for the forecast period 2014 to 2020, considering 2013 as the base year.
In addition, the global market for mouth ulcers treatment is segmented based on the indication. The segment is categorized into aphthous stomatitis, oral lichen planus and others. The market for these indications of mouth ulcers treatment has been extensively analyzed based on demand of various treatment options among population. The market size and forecast in terms of USD million for each segment has been provided for the period 2012 to 2020. The report on the mouth ulcers treatment market also provides % compounded annual growth rate (CAGR) for each market segment and sub segment for the forecast period 2014 to 2020, considering 2013 as the base year.


Likewise, the global market for mouth ulcers is segmented based on drug class into corticosteroid, anesthetic, analgesic, antihistamine and antimicrobial. The market for these drug classes has been extensively analyzed based on consistency, effectiveness and sales revenue of the various classes developed by the manufacturers. The market size and forecast in terms of USD million for each drug class has been provided for the period 2012 to 2020. The report on the mouth ulcers treatment market also provides % compounded annual growth rate (CAGR) for each of the aforementioned market segment and sub segment for the forecast period 2014 to 2020, considering 2013 as the base year.

Geographically, the mouth ulcers treatment market has been categorized into four major regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). The market size and forecast for each of these regions have been provided for the period 2012 to 2020 along with CAGR (%) for the forecast period 2014 to 2020. The research study also incorporates the competitive scenario of major players in these regions.

A list of recommendations has been provided for new entrants to help establish a strong presence and for existing market players to increase their market share. The report concludes with the profiles of major players in the mouth ulcers treatment market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major market players profiled in this report includes include 3M Healthcare, Bristol Meyer Squibb Company, ECR Pharmaceuticals, GlaxoSmithKline plc and Church & Dwight Co, Inc. among others.


The global mouth ulcers treatment market is segmented as follows:

Mouth Ulcers Treatment Market, by Formulation
Mouthwash
Gel
Spray
Lozenge

Mouth Ulcers Treatment Market, by Indication
Aphthous Stomatitis
Oral Lichen Planus
Others

Mouth Ulcers Treatment Market, by Drug Class
Corticosteroid
Anesthetic
Analgesic
Antihistamine
Antimicrobial

Mouth Ulcers Treatment Market, by Geography
North America
Europe
Asia-Pacific
Rest of the World

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Sunday, 16 November 2014

Hospital Pharmaceuticals Market Overview 2014 - 2020

The global hospital pharmaceuticals market was valued at USD 26.5 billion in 2013 and is estimated to reach USD 11.6 billion by 2020 declining with a CAGR of (10.5)% from 2014 to 2020.

The report defines hospital pharmaceuticals as drugs that are exclusively administered in hospital and professional healthcare facilities that encompass both in-patient as well as out-patient departments. Hospital pharmaceuticals market which had been experiencing slumps in past three to four years due to economic slowdown, patent and exclusivity loss of various orphan and blockbuster drugs is expected to recover at a rapid pace. Over a decade there has been a considerable rise in several chronic disorders that can only be treated in hospital setting such as renal failure, canter, stroke, Alzheimer's disease and angina which is expected to boost hospital pharmaceuticals market in forthcoming years.


According to World Health Organization (WHO), coronary heart diseases across the globe accounts for over 7.5 million mortalities annually. Moreover as per an analysis by Centers for Disease Control and Prevention (CDC), each year stroke kills approximately 130,000 Americans of which about 87% of them are ischemic strokes. Approximately 5.1 million people in the United States suffered from heart failure in 2013. The aforementioned statistics clearly depict the latent potential for growth owing to substantial rise in various disease indications which in last two years accounted for major source of revenue for hospital pharmacies.

The report studies the hospital pharmaceuticals market from two perspectives: major therapeutic class and indications. Market by therapeutic class includes all major drug classes that are majorly prescribed and sold in hospital pharmacies. Market by indication is segmented into six major disorders: cardiology, oncology, nephrology and urology, neurology, pain and anti-infectives. Among the mentioned indications, oncology and cardiology are key markets share declining at a CAGR of (13.01)% and (9.38)% respectively. Decline in growth rate for both the markets is majorly attributed to increasing number of drugs losing their exclusivity during the forecast period (2014-2020). Billion dollar cardiovascular medicines that are getting off patent include Exforge HCT (amlodipine/hydrochlorothiazide/valsartan), Benicar HCT (hydrochlorothiazide and olmesartan) and VESIcare (Solifenacin Succinate) in 2014, 2016 and 2018 respectively. Furthermore various billion dollar oncology drugs which will get off patent in next 5 years comprise Gleevec (Imatinib Mesylate), Tarceva (erlotinib), Zytiga (Abiraterone Acetate) and Velcade (bortezomib).


Rise in emergency department visits and increased per capita spending of patients across the globe are some of the major drivers escalating the growth of the overall market. Emergency department visits accounted for 7.4% of the total hospital visits in the U.S. in 2011 compared to 2.3% in 2010. Healthcare Cost and Utilization Project (HCUP) statistical brief data estimated that emergency department discharges increased five times (359 patients per 1,000 people) in the U.S. in 2011 compared to 2010. A large number of new molecular entities are also anticipated to be launched during the forecast period. These primarily include therapeutic areas such as cancer, neurological disorders, infections and cardiovascular diseases. All these factors would increase the global spending on medicines. Moreover, global spending on medicines is expected to increase from USD 1 trillion in 2014 to USD 1.2 trillion by 2017. Such factors are expected to boost the market for hospital pharmaceuticals market especially in case of generic drugs.


Geographically, North America market accounted for the largest share in 2013 due to 2013 due to favorable reimbursement policies, high awareness, rising per capita income, increased spending on the healthcare and greater depth of marketing efforts by key players. Total spending on healthcare in the U.S. increased from USD 320 million in 2012 to USD 330 million in 2013 depicting an increase of per capita spending by 1%. Presence of sound intellectual property in the European Union countries and presence of high quality pharmaceutical research organizations are among the few prominent drivers. Whereas, fragmented pricing system and improper reimbursement scenario and regulatory framework for clinical trials are key restraints to the European hospital pharmaceuticals market. Asia Pacific and Rest of the World are among the fastest growing markets for hospital pharmaceuticals due to the presence of large population base, aging population suffering from chronic diseases and increasing disposable income.

Browse the full press release of Hospital Pharmaceuticals Market: http://www.transparencymarketresearch.com/pressrelease/hospital-pharmaceuticals-market.htm

Leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis.

The hospital pharmaceuticals market is segmented as follows:


Global Hospital Pharmaceuticals Market, by Major Therapeutic Class

Cardiology
Anti-Adrenergic Drugs
Calcium Channel Blockers
Diuretic Drugs
Anti-Arrhythmic Drugs

Others
Oncology
Alkylating Agents
Anti-Metabolites
Hormonal Agents
Immunomodulating Agents
Miscellaneous Drugs

Nephrology and Urology
Diuretic Agents
Anti-Hypertensive Agents
Phosphate Binders
Anticholinergic Drugs
5-Alpha Reductase Inhibitors

Neurology
Anti-Anxiety Agents
Detail2Anti-Migraine Drugs
Antidepressant Drugs
Anti-Psychotic Drugs

Pain
Anticonvulsant Drugs
Anesthetic Drugs
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Opioids
Non-Narcotics Analgesic Drugs

Infection
Antibacterial Drugs
Antiviral Drugs
Antifungal Drugs
Antiparasite Drugs

Global Hospital Pharmaceuticals Market, by Major Indications

Cardiology
Coronary Heart Diseases
Stroke
High Blood Pressure
Heart Failure
Others

Oncology
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Others

Nephrology and Urology
Acute Kidney Failure
Chronic Kidney Diseases
Glomerular Diseases
Diabetes
Others

Neurology
Epilepsy
Alzheimer;s Disease
Parkinson;s Disease
Multiple Sclerosis
Others

Pain
Neuropathic Pain
Fibromyalgia
Osteoarthritis
Rheumatoid Arthritis
Cancer Pain

Infection
Detail1Tuberculosis
Pneumonia
Hepatitis A
Hepatitis B
Candida Infection
Fungal Meningitis
Shigellosis
Amoebiasis
Other

Global Hospital Pharmaceuticals Market, by Geography
North America
Europe
Asia Pacific
Rest of the World (RoW)


About Us:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:
Sheela AK
State Tower, 90 State Street,
Suite 700, Albany NY - 12207
USA/Canada Toll Free: 866-552-3453

Thursday, 6 November 2014

Growth Netupitant Palonosetron FDC Market 2012 - 2018

The global Netupitant - Palonosetron FDC sales are expected to reach USD 515.0 million by 2018. The global Chemotherapy-induced nausea and vomiting (CINV) market is estimated to reach USD 1.7 billion by 2015 at a growth rate of 7.1%, whereas country such as South Africa is estimated to constitute 9% of the CINV market by 2015, due to prevalent cancer related conditions and subsequent increase in CINV patient pool. Asian region is expected to witness largest patient share for CINV contributing majorly to the total CINV patient pool. Hence, Asian market is expected to have huge growth potential for Netupitant - Palonosetron FDC.


Chemotherapy is one of the treatment options utilized by oncologists in treating different types of cancers. Nausea and vomiting are the most common side-effects experienced by cancer patients when administered with chemotherapy. Netupitant-palonosetron, which is currently in Phase III trials helps in preventing CINV. The blockage of P/NK1 receptors by Netupitant in the central nervous system inhibits the binding of endogenous tachykinin neuropeptide substance and this result in preventing the chemotherapy-induced nausea and vomiting. Moreover, Palonosetron helps in the blockage of serotonin at 5-hydroxytryptamine type 3 (5-HT3) receptors and it also helps in the chemotherapy-induced nausea and vomiting.

Netupitant-Palonosetron FDC is estimated to answer significant unmet needs of the CINV market post its launch that is expected to be commercialized in 2014, as it would overcome the problems associated with current treatment with 5-HT3 receptor antagonists. Similar to Emend, Netupitant-Palonosetron FDC would gain considerable patient pool after its estimated launch in 2014, and subsequently match the patient share of Aloxi by 2018. Netupitant-Palonosetron FDC sales are expected to reach an estimated USD 515.0 million USD by 2018. FDC combination of 5-HT3 receptor antagonist and neurokinin-1 (NK1) receptor antagonist have shown better efficacy results in Phase II clinical trials for CINV patients and would thus lead to high uptake due to shifting physician and patient preference pattern towards better treatment for CINV.

The lack of approval to any other antagonist for the prevention of delayed-onset CINV in patients getting highly emetogenic chemotherapy, Palonosetron is expected to witness higher growth. It is expected to grow at a higher rate during the forecasted period in both developed and developing regions such as South Africa and Asia among others.


CINV can cause cancer patients to withdraw from therapy due to increased medical costs, often leading to higher mortality and higher medical spending. So, patients and providers would realize the benefits of finding alternative CINV therapies, such as Netupitant-Palonosetron FDC.


New entrants to this market have historically benefited from rapid uptake, driven both by clinical advantages and by favorable reimbursement dynamics, from which Netupitant-Palonosetron FDC is poised to benefit upon approval.


There is certain advantage of the Netupitant - Palonosetron as it would be the only FDC approved for treating chemotherapy induced nausea and vomiting that is likely to drive this market in the near future. Moreover, it is effective in the body for longer period of time and will help in achieving better patient compliance. However, lack in the number of clinical trials is likely to slower the growth of this market but the rising cancer population is likely to further create an opportunity in this market.

Browse all Medical Devices Market Research Reports

About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Thursday, 30 October 2014

Membrane Technology Market Growth 2014 - 2019

The global membrane technology market for pharmaceutical, biopharma and life sciences is estimated at USD 6,461.3 million in 2013 and is expected to grow at a CAGR of 9.1% from 2014 to 2019, to reach an estimated value of USD 10,886 million in 2019.

Browse Global Membrane Technology Market Report with Full TOC at http://www.transparencymarketresearch.com/membrane-technology-market.html

The membrane technology market is witnessing significant growth due to increasing research and development and production in pharmaceutical, biopharmaceutical and life sciences industries. Thus, rise in pharmaceutical production and increasing number of membrane technology applications worldwide are driving the growth of membrane technology in pharmaceutical, biopharmaceutical and life sciences industries.

Additionally, stringent regulations and usage of single-use disposable technique are playing a major role in growth of the membrane technology market. Presence of various filtration techniques such as ultrafiltration, nanofiltration and microfiltration under membrane technology has increased its acceptance in pharmaceutical, biopharmaceutical and life science industries for separation and purification of components and biomolecules, over conventional techniques. However, the market faces some restraints such as effects of membrane fouling, high operational and investment cost and limitation of membrane materials. As a result, the market is expected to grow at a CAGR of about 9.1% during 2014-2019.

Globally, North America is the largest market for membrane technology in pharmaceutical, biopharmaceutical and life sciences industries. The U.S. is the world's largest market for pharmaceutical and biopharmaceutical products. According to the European Federation of Pharmaceutical Industries and Associations, North America accounted for about 41% of global pharmaceutical sales in 2012. Pharmaceutical and biopharmaceutical firms in the U.S. conduct 80% of research and development of innovative medicines in the world. The pharmaceutical market in the U.S. is highly regulated by the Food and Drug Administration (FDA).


In Europe, membrane technology is a rapidly growing sector with many associations, organizations and societies actively involved in expansion and implementation of this technology in various industries including pharmaceutical, biopharmaceutical and life sciences. Organizations in Europe such as the European Desalination Society (EDS), and European Membrane House (EMH) promote membrane technology usage in universities, companies, research institutes and government agencies.

However, Asia is the fastest growing region in the membrane technology market due to continuous development in pharmaceutical and biopharmaceutical industries. The region is witnessing double-digit growth (average annual growth rate of 13%) in pharmaceutical and biopharmaceutical industries due to a large population base, increasing healthcare awareness, rising incidence of chronic diseases and higher government healthcare spending.

GE Healthcare and 3M Healthcare are the leading players in the global market of membrane technology in pharmaceutical, biopharma and life sciences. Other major players of the membrane technology market include Sartorius, Merck Millipore, Koch Membrane System, Novasep and others.

The global market of membrane technology in pharmaceutical, biopharma and life sciences is segmented as follows:

Membrane Technology Market, By Technology
Ultrafiltration
Microfiltration
Nanofiltration
Chromatography

Membrane Technology Market, by Geography

North America
U.S.

Europe
Switzerland
Germany
Italy
U.K.
Ireland
France

Asia
China
India
Japan
Malaysia
Singapore
Rest of the World (RoW)

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Wednesday, 29 October 2014

Meningococcal Vaccines Market Share 2013 - 2019:Transparency Market Research

Global meningococcal vaccines market has the potential of growing at a CAGR of 14.9% during 2013 and 2019. Growing at this pace, this market that valued US$1.5 billion in 2012 could achieve a net worth of US$3.7 billion by 2019.

Browse Meningococcal Vaccines Market Report With Full TOC http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html

Various strains of meningococcal bacteria cause serious infection to the thin lining surrounding the brain and spinal cord. The infection results in severe brain damage and can be fatal in 50% cases if left untreated. The high fatality rate of meningococcal disease is generally considered as a medical emergency. This is why, federal governments of various countries are actively involved in efforts for spreading awareness about the severity of the condition. Many government bodies are also involved in the research, development, and also the distribution of meningococcal vaccines regionally.
Transparency Market Research’s report on the global meningococcal vaccines market presents an all-inclusive overview of the market and its various segments.
The report mainly focuses on major market segments based on the types of vaccines available in the meningococcal vaccine market, such as Polysaccharide Vaccines, Conjugate Vaccines, Combination Vaccines, and the vaccines in pipeline. The product types are further segmented according to the brands that feature them. An overview of geographically specific active regional markets is also included in the report.
Conjugates are expected to lead the global meningococcal vaccines market in the future. By observing growth at a CAGR of 12.9%, this product segment could amass net worth of nearly US$2.5 billion by 2019. Amongst the various meningococcal vaccines in pipeline currently, Novartis’s Bexsero is expected to gain market shares at the fastest pace, an expected 24.7%, during the forecast period.


The Department of Health, UK, states that Baxsero will be the first vaccine for serogroup B in the meningococcal vaccines market after its launch in the second quarter of 2014. Pfizer’s MnB rLP2086 is another potential future vaccine that is currently in its third phase of trial. The launch of this vaccine, which has received a Breakthrough Therapy status from the U.S. FDA, is expected to change the complete outlook of this market by intensifying competition.


Geographically, North America was the leading shareholder of the global meningococcal vaccines market in 2011 due to government led immunization programs and favorable research and development initiatives undertaken by major drug companies in this region. Also, every year nearly 1,000 to 2,600 people in the U.S. contract meningitis from various strains of the bacteria. However, vaccines for only the serotypes A, C, Y, and W-135 are available in the U.S. market.


Regional market of Asia Pacific is expected to grow at the fastest pace in the global meningococcal vaccines market, at an estimated CAGR of 17.1%, by the end of 2019. Major drivers of growth in these regional markets are the low manufacturing cost of vaccines, and transfer of novel manufacturing technologies from developed countries to these regions.


About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com